Valley Wealth Managers Inc. Has $18.46 Million Holdings in Pfizer Inc. $PFE

Valley Wealth Managers Inc. trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 7.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 741,190 shares of the biopharmaceutical company’s stock after selling 62,500 shares during the quarter. Valley Wealth Managers Inc.’s holdings in Pfizer were worth $18,456,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after purchasing an additional 7,031,162 shares in the last quarter. State Street Corp raised its position in shares of Pfizer by 0.9% in the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock valued at $7,620,747,000 after buying an additional 2,786,098 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Pfizer by 1.4% in the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after buying an additional 869,175 shares during the period. Fisher Asset Management LLC grew its position in Pfizer by 1.9% during the third quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock worth $1,255,860,000 after buying an additional 897,786 shares in the last quarter. Finally, Legal & General Group Plc grew its position in Pfizer by 8.6% during the third quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company’s stock worth $1,063,565,000 after buying an additional 3,296,415 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on PFE shares. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a report on Saturday. Royal Bank Of Canada restated an “underperform” rating and issued a $25.00 price target on shares of Pfizer in a research report on Monday, April 20th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. Barclays initiated coverage on shares of Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price objective for the company. Finally, HSBC raised their target price on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $28.74.

Pfizer Trading Up 0.5%

Shares of PFE stock opened at $25.82 on Tuesday. Pfizer Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $28.75. The stock’s fifty day moving average price is $27.09 and its two-hundred day moving average price is $26.17. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The company has a market cap of $147.16 billion, a PE ratio of 19.71 and a beta of 0.35.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter in the previous year, the firm earned $0.92 EPS. Pfizer’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts predict that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.7%. Pfizer’s payout ratio is presently 131.30%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer advanced its oncology pipeline with FDA approval for VEPPANU (vepdegestrant) in endocrine-resistant advanced breast cancer, plus positive Phase 3 data for ELREXFIO in relapsed or refractory multiple myeloma, both of which could support longer-term growth. Article
• Positive Sentiment: Pfizer also extended U.S. patent protection for VYNDAMAX to 2031, improving cash-flow visibility for a key cardiology product and easing some expiration risk. Article
• Positive Sentiment: Analysts are taking a closer look at Pfizer’s turnaround story, with coverage highlighting that its push into oncology and next-generation therapies could help offset the slowdown after the COVID windfall. Article
• Neutral Sentiment: Recent articles focused on whether Pfizer’s high dividend yield remains safe after a drop in net income, but they did not point to an immediate cut or a major near-term change in capital returns. Article
• Neutral Sentiment: Pfizer remains a widely watched stock, and several commentaries compare its slower rebuilding phase with peers like Eli Lilly, underscoring that investors are still waiting for clearer growth momentum. Article
• Negative Sentiment: Reports noting Pfizer’s Q1 net income decline and debate over dividend safety may weigh on sentiment if investors worry profitability is still under pressure. Article

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.